ADC Therapeutics (ADCT) Stock Statistics & Valuation Metrics

ADC Therapeutics has a market cap or net worth of $122.57M. The enterprise value is $64.32.

ADC Therapeutics has 127,667,694 shares outstanding. The number of shares has decreased by -2.65% in one year.

ADC Therapeutics’s return on equity (ROE) is 0.77 and return on invested capital (ROIC) is -42.29%.

The current PE Ratio of ADC Therapeutics is ―. ADC Therapeutics’s PEG ratio is 0.10.

In the last 12 months, ADC Therapeutics had revenue of 81.36M and earned -142.62M in profits. Earnings per share was -1.12.

In the last 12 months, operating cash flow was -102.27M and capital expenditures -45.63K, giving a free cash flow of -102.31M billion.

ADC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

ADC Therapeutics upcoming earnings date is Nov 10, 2026, Before Open (Confirmed).

ADC Therapeutics as a current ratio of 4.37, with Debt / Equity ratio of -182.78%

In the past 12 months, ADC Therapeutics has paid -157.00K in taxes.

ADC Therapeutics EV to EBITDA ratio is -7.01, with an EV/FCF ratio of -4.43.

ADC Therapeutics has $219.11M in cash and marketable securities with $417.11M in debt, giving a net cash position of -$198.00M billion.

Gross margin is 88.75%, with operating margin of -133.21%, and net profit margin of -175.31%.

The average price target for ADC Therapeutics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy